03/05/2019 Transcatheter Heart Valves Greece 2019 | N. Kleiman | Is paravalvular regurgitation after TAVR still an important consideration in 2019?

info_icon

 

Δηλώνω υπεύθυνα ότι είμαι γιατρός ή εξασκώ παραϊατρικό επάγγελμα |

I hereby declare that I am a medical professional  

 

Συμφωνώ | Άκυρο

582 VIEWS EXPANDCOLLAPSE Αρχείο

Share

91,021 total
707 live
582 video
40,685 photo
Views:

3/5Αίθουσα Banquet Hall, MAICC -
14:00-15:45 TAVI Session III – TAVR dilemmas and complications
Πρόεδροι: D. Iliopoulos,G. Hahalis,V. Pyrgakis,S. Tzeis
14:00-14:15 Incidence, predictors and consequences of new LBBB and new PPM after TAVR
L. Papavasileiou
14:15-14:30 Is paravalvular regurgitation after TAVR still an important consideration in 2019?
N. Kleiman
14:30-14:45 A Selective versus Routine Minimalist Strategy. Is every patient eligible?
S. Kapadia
14:45-15:00 Management of Coronary Disease in AS Patients: Important Treatment Considerations (When to consider CABG, timing of PCI and TAVR, and completeness of revascularization)
M. Οto
15:00-15:15 To crack or not to crack? The role for fracturing bioprosthetic valves during ViV procedures
M. Kasel
15:15-15:30 Live-in-a-box TAVR
15:30-15:45 Discussion
Σχολιαστές: I. Chlorogiannis,K. Dimitriadis,A. Zacharoulis


Το 8o Συνέδριο Διακαθετηριακής Θεραπείας Καρδιακών Βαλβιδοπαθειών θα μεταδοθεί ζωντανά στο Livemedia
3 - 4 Μαίου 2019. Το Συνέδριο διοργανώνεται από το Διαγνωστικό Θεραπευτήριο Κέντρο Αθηνών Υγεία και θα πραγματοποιηθεί στο Μέγαρο Μουσικής Αθηνών.

Για περισσότερες πληροφορίες πατήστε εδώ.

 
Sort by Date | Views
G. Pattakos | Latest TAVR Randomized Trials... 655
M. Vavuranakis | High-Quality TAVR: Does... 631
S. Prapas | The selection of SAVR devices... 660
P. Dedeilas | Rapid Deployment Surgical... 643
WELCOME NOTES 617
A. Chalapas | CT Imaging of Bicuspid Aortic... 644
N. Van Mieghem | TAVR will be the treatment... 714
D. Angouras | Most Bicuspid aortic valves... 628
S. Kodali | Strokes After TAVR and SAVR:... 599
R. Mehran | What’s Holding Back Cerebral... 583
M. Οto | TAVR in the patient with significant... 583
A. Halapas | Live in a Box | TAVR Session... 635
L. Papavasileiou | Incidence, predictors... 647
N. Kleiman | Is paravalvular regurgitation... 582
S. Kapadia | A Selective versus Routine... 565
M. Οto | Management of Coronary Disease... 587
M. Chirssoheris | Live in a Box | TAVI Session... 587
A. Katsaros | Impact of valvular heart disease... 622
A. Patrianakos | Patient-prosthesis mismatch... 608
E. Anagnostou | Moderate aortic stenosis... 768
G. Pattakos | Minimally invasive surgery... 627
S. Kodali | In hospital mortality after... 553
G. Giamouzis - G. Karatasakis | JOINT SESSON... 603
S. Kapadia | TAVR for All? New insights... 558
J. Kisslo | Defining Secondary Mitral Regurgitation:... 603
S. Kar | Mitraclip for Functional Mitral... 568
D. Klettas | Exercise-stress echocardiography... 791
K. Spargias | Mitraclip vs. PASCAL. Similarities... 660
K. Papadopoulos | Lessons from the MITRA-FR... 740
S. Kar | Percutaneous mitral repair after... 587
N. Kleiman | Who are the best candidates... 606
F. Maisano | Lessons from an International... 630
M. Chrissoheris | Echocardiographic evaluation... 614
A. Pitsis | Mitral Valve-in-valve and valve-in-ring... 571
J. Velianou | Results of valve-in-MAC (mitral... 562
S. Kar | Currently enrolling TMVR and TTVR... 626
F. Maisano | You can’t beat safety and simplicity:... 598
N. Baikoussis - K. Bellos - E. Petropoulou... 578
K. Papadopoulos | Live in a box Mitraclip... 587
V. Voudris | A growing conundrum: Coronary... 600
N. Van Mieghem | Mechanisms of coronary... 565
N. Bouboulis | Hybrid beating heart bypass... 560
A. Manginas | Guidelines and classification... 590
R. Mehran | TAVR plus/minus AFib and/or... 595
G. Dangas | The Spectrum of Leaflet Thrombosis... 555
Discussion | TAVI Session IV – Avoiding Pitfalls 570
G. Pattakos |Live in a Box | TAVI Session... 565
M. Kasel | To crack or not to crack? The... 624
K. Spargias | Supra-annular TAVR devices.... 578
J. Velianou | To split or not to split?... 611
M. Kasel | The rapid emergence of transcaval... 525
P. Dardas | TAVR in the decompensated patient... 411
K. Dimitriadis | Transcatheter Heart Valves... 398
Discussion | TAVR Session V – Dealing with... 394
A. Οto - Transcatheter Heart Valves Greece... 410
S. Kapadia | Transcatheter Heart Valves Greece... 390
Σ.Παττακός | Transcatheter Heart Valves Greece... 385
K. Spargias | How far should we push the... 445
M. Chrissoheris | Live-in-a-box TAVR | TAVR... 414
A. Holzamer | The ACCURATE Neo TAVR system.... 406
L. Michalis | The PORTICO TAVR system. Program... 388
V. Martzaklis | Medtronic Structural Heart... 422
M. Kasel | What to expect in the near future... 372
L. Michalis | A Deep Dive Into TAVR Cost-Effectiveness... 372
M. Kasel | TAVR device selection in the... 397
J. Kisslo | Three-Dimensional Echocardiography... 412
F. Maisano | Patient selection for transcatheter... 414
M. Chrissoheris | Advanced echocardiography... 392
K. Spargias | Technical tips and tricks... 424
V. Ninios | An often Challenging MitraClip... 383
A. Tzifa | Transcatheter valve-in-valve... 442
A. Pitsis | Minimally invasive surgery for... 404
S. Pattakos | The Structural Heart and Valve... 381
C. Arampatzis | My best and/or my worst... 396
J. Iakovou | My best and/or my worst Structural... 377
G. Katsimagklis | My best and/or my worst... 386
D. Nikas | My best and/or my worst Structural... 404
K. Perreas | My best and/or my worst Structural... 382
K. Spiliotopoulos | My best and/or my worst... 393
K. Triantafyllou | My best and/or my worst... 325
D. Tsikaderis | My best and/or my worst... 371
I. Zarifis | My best and/or my worst Structural... 382
Closing of the conference 362
03/05 Banquet Hall, MAICC
09:00 - 11:00
TAVI Session I – TAVR Technology in a Rapidly-Evolving Era 

Evaluated
Evaluation
09:00 - 09:15
Latest TAVR Randomized Trials

Evaluated
Evaluation

Speaker: G. Pattakos(   )

09:15 - 09:30
High-Quality TAVR: Does a minimum volume requirement still make sense?

Evaluated
Evaluation

Speaker: M. Vavuranakis(   )

09:30 - 09:45
The selection of SAVR devices in the TAVR era

Evaluated
Evaluation

Speaker: S. Prapas(   )

09:45 - 10:00
Rapid Deployment Surgical Valves with Minimally invasive techniques. Can they compete with TAVR?

Evaluated
Evaluation

Speaker: P. Dedeilias

10:00 - 10:15
TAVR for low-risk patients with a self-expanding valve

Evaluated
Evaluation

Speaker: N. Kleiman

10:15 - 10:30
Live-in-a-box TAVR

Evaluated
Evaluation
10:45 - 11:00
Discussion

Chairmen: I. Goudevenos, J. Kanakakis, D. Sionis, P. Vardas

Commentators: S. Karagiannis, G. Makos, A. Tzikas

11:00 - 11:30
WELCOME NOTES 

Evaluated
Evaluation

Chairmen: S. Pattakos, S. Konstantinidis, I. Goudevenos, D. Tousoulis, P. Vardas, A. Kartapanis

11:30 - 13:30
TAVR Session II – TAVR on the Uprise. How do we deal with complex situations? 

Evaluated
Evaluation
12:00 - 12:10
CT Imaging of Bicuspid Aortic Valve Disease. Anatomic patterns favorable and unfavorable for TAVR and factors influencing device selection

Evaluated
Evaluation

Speaker: A. Chalapas(   )

12:10 - 12:20
TAVR will be the treatment of choice for bicuspid aortic valve disease in the future!

Evaluated
Evaluation

Speaker: N. Van Mieghem(   )

12:20 - 12:30
Most Bicuspid aortic valves (especially In younger low-risk patients) will remain in the surgical domain!

Evaluated
Evaluation

Speaker: D. Angouras(   )

12:30 - 12:40
Strokes After TAVR and SAVR: Incidence in the "Modern Era" and Key Messages

Evaluated
Evaluation

Speaker: S. Kodali(   )

12:40 - 12:50
What’s Holding Back Cerebral Embolic Protection in TAVR? Data or Money?

Evaluated
Evaluation

Speaker: R. Mehran(   )

12:50 - 13:00
TAVR in the patient with significant native or bioprosthetic mitral and/or tricuspid valve disease

Evaluated
Evaluation

Speaker: M. Οto

13:00 - 13:15
Live-in-a-box TAVR

Evaluated
Evaluation
13:15 - 13:30
Discussion

Chairmen: M. Argiriou, S. Foussas, E. Pissimisis, C. Tsioufis

Commentators: K. Aznaouridis, V. Androutsopoulou, S. Makrigiannis

13:30 - 14:00
BREAK 

14:00 - 15:45
TAVI Session III – TAVR dilemmas and complications 

Evaluated
Evaluation
14:00 - 14:15
Incidence, predictors and consequences of new LBBB and new PPM after TAVR

Evaluated
Evaluation

Speaker: L. Papavasileiou(   )

14:15 - 14:30
Is paravalvular regurgitation after TAVR still an important consideration in 2019?

Evaluated
Evaluation

Speaker: N. Kleiman(   )

14:30 - 14:45
A Selective versus Routine Minimalist Strategy. Is every patient eligible?

Evaluated
Evaluation

Speaker: S. Kapadia(   )

14:45 - 15:00
Management of Coronary Disease in AS Patients: Important Treatment Considerations (When to consider CABG, timing of PCI and TAVR, and completeness of revascularization)

Evaluated
Evaluation

Speaker: M. Οto

15:00 - 15:15
To crack or not to crack? The role for fracturing bioprosthetic valves during ViV procedures

Evaluated
Evaluation

Speaker: M. Kasel

15:15 - 15:30
Live-in-a-box TAVR

Evaluated
Evaluation
15:30 - 15:45
Discussion

Evaluated
Evaluation

Chairmen: D. Iliopoulos, G. Hahalis, V. Pyrgakis, S. Tzeis

Commentators: I. Chlorogiannis, K. Dimitriadis, A. Zacharoulis

15:45 - 16:00
Break 

Evaluated
Evaluation
16:00 - 17:30
JOINT SESSON I 

Aortic and Mitral Club

Evaluated
Evaluation
16:00 - 16:15
In hospital mortality after TAVR. Common and uncommon causes

Evaluated
Evaluation

Speaker: S. Kodali(   )